This company has been marked as potentially delisted and may not be actively trading. Edge Therapeutics (EDGE) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock EDGE vs. MENS, MOR, GMTX, CALT, ZYME, SBTX, MBX, NLTX, CYBN, and BIOAShould you be buying Edge Therapeutics stock or one of its competitors? The main competitors of Edge Therapeutics include Jyong Biotech (MENS), MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Neoleukin Therapeutics (NLTX), Cybin (CYBN), and BioAge Labs (BIOA). Edge Therapeutics vs. Its Competitors Jyong Biotech MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks Silverback Therapeutics MBX Biosciences Neoleukin Therapeutics Cybin BioAge Labs Edge Therapeutics (NASDAQ:EDGE) and Jyong Biotech (NASDAQ:MENS) are both pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk. Is EDGE or MENS more profitable? Jyong Biotech's return on equity of 0.00% beat Edge Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Edge TherapeuticsN/A -81.29% -56.92% Jyong Biotech N/A N/A N/A Does the media favor EDGE or MENS? In the previous week, Jyong Biotech had 6 more articles in the media than Edge Therapeutics. MarketBeat recorded 6 mentions for Jyong Biotech and 0 mentions for Edge Therapeutics. Jyong Biotech's average media sentiment score of 0.44 beat Edge Therapeutics' score of 0.00 indicating that Jyong Biotech is being referred to more favorably in the news media. Company Overall Sentiment Edge Therapeutics Neutral Jyong Biotech Neutral Do insiders and institutionals hold more shares of EDGE or MENS? 28.0% of Edge Therapeutics shares are owned by institutional investors. 37.1% of Edge Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation and earnings, EDGE or MENS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdge TherapeuticsN/AN/A-$40.86MN/AN/AJyong BiotechN/AN/AN/AN/AN/A SummaryJyong Biotech beats Edge Therapeutics on 4 of the 6 factors compared between the two stocks. Get Edge Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EDGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EDGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDGE vs. The Competition Export to ExcelMetricEdge TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.32B$833.53M$5.82B$9.77BDividend YieldN/A4.84%4.40%4.06%P/E RatioN/A1.1831.3026.05Price / SalesN/A152.90433.14108.31Price / CashN/A19.5638.0259.36Price / Book43.966.649.536.60Net Income-$40.86M-$4.94M$3.26B$265.65M Edge Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDGEEdge TherapeuticsN/A$41.76+1.4%N/A+1,165.5%$1.32BN/A0.00N/AMENSJyong BiotechN/A$44.74+13.0%N/AN/A$3.01BN/A0.0031News CoverageMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive NewsGMTXGemini TherapeuticsN/A$60.72-0.6%N/A+23.8%$2.63BN/A-60.7230High Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks1.7971 of 5 stars$14.36+0.4%$21.43+49.2%+32.6%$1.08B$122.87M-9.57460SBTXSilverback TherapeuticsN/A$14.47-8.5%N/A+4.2%$521.76MN/A-5.9883Positive NewsHigh Trading VolumeMBXMBX Biosciences1.9602 of 5 stars$14.72+11.4%$37.75+156.5%N/A$494.50MN/A-3.2436NLTXNeoleukin TherapeuticsN/A$20.20-4.3%N/A-42.8%$189.84MN/A-6.5090High Trading VolumeCYBNCybin2.4164 of 5 stars$7.06-1.5%$85.00+1,104.0%N/A$166.55MN/A-1.6150News CoverageAnalyst RevisionBIOABioAge LabsN/A$4.55+2.0%N/AN/A$159.89MN/A0.00N/AHigh Trading Volume Related Companies and Tools Related Companies Jyong Biotech Competitors MorphoSys Competitors Gemini Therapeutics Competitors Calliditas Therapeutics AB (publ) Competitors Zymeworks Competitors Silverback Therapeutics Competitors MBX Biosciences Competitors Neoleukin Therapeutics Competitors Cybin Competitors BioAge Labs Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDGE) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edge Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edge Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access